Updated NETs Clinical Trials

• The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support

  Conditions: Neuroendocrine Cervical Cancer; Patient Support Interventions: Other: Questionnaire Sponsors: M.D. Anderson Cancer Center Recruiting

• Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

  Conditions: Neuroendocrine Tumors Interventions: Drug: surufatinib; Drug: Somatostatin Analogs Sponsors: West China Hospital; First Affiliated Hospital Xi'an Jiaotong University; National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; The First Affiliated Hospital of Zhengzhou University; Beijing 302 Hospital; China-Japan Friendship Hospital Active, not recruiting

• Breathwork and Stress: Investigating the Mechanisms of Action and Effectiveness of Breathing Interventions in Modulating the Psychophysiological Response to Acute Stress Test

  Conditions: Healthy Adult Participants; Acute Stress Reaction; Stress Biomarkers; Healthy Interventions: Behavioral: Coherent Breathing (6 bpm); Behavioral: Sham Breathing (15 bpm) Sponsors: Medical University of Bialystok Not yet recruiting

• Akk09 in Adults With Constipation

  Conditions: Constipation Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Maltodextrin Sponsors: Wecare Probiotics Co., Ltd. Not yet recruiting

• Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction

  Conditions: SIAD - Syndrome of Inappropriate Antidiuresis Interventions: Dietary Supplement: urea Sponsors: University of Turin, Italy Recruiting

• ECCA's Turkish Validity and Reliability Study and Comparison With Other Cognitive Assessment Tests

  Conditions: Electroconvulsive Therapy (ECT); Electroconvulsive Therapy Cognitive Assessment (ECCA); Montreal Cognitive Assessment (MoCA); Turkish Adaptation; Cognitive Assessment Interventions: Device: ElectroConvulsive Therapy Cognitive Assessment (ECCA) Sponsors: Pamukkale University Enrolling by invitation

• A Study on the Efficacy and Safety of Endoscopic Ultrasound-guided Gastro-/Duodeno-cholecystostomy for the Treatment of Gallstones.

  Conditions: Gall Stones; Gall Stones (& [Calculus - Gall Bladder]) Interventions: Device: cholecystolithotomy Sponsors: Tongji Hospital Enrolling by invitation

• A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma

  Conditions: Advanced Neuroendocrine Carcinoma Interventions: Drug: SHR-A1904 Injection Sponsors: Beijing GoBroad Hospital Not yet recruiting

• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

  Conditions: Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Interventions: Drug: Chidamide; Drug: Sintilimab; Drug: Bevacizumab Sponsors: Sun Yat-sen University Recruiting

• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  Conditions: Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer; Small Cell Carcinomas of Non-lung Origin; Non-small Cell Lung Cancer (NSCLC); Prostate Cancer; Ovarian Cancer; Renal Carcinoma (Clear and Non-clear Cell); Head and Neck Squamous Cell Carcinoma (HNSCC); Hepatic Cancer; Gastric Cancer; Triple-negative Breast Cancer (TNBC) Interventions: Drug: EXS74539 Sponsors: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Recruiting

• Prospective Cohort Study of Pheochromocytoma/Paraganglioma

  Conditions: Pheochromocytoma; Paraganglioma; Hemodynamic Instability; Intraoperative Complications Sponsors: Peking Union Medical College Hospital Not yet recruiting

• 18F-FAPI PET/CT and MRI in Gastric Cancer

  Conditions: Gastric Cancer Interventions: Diagnostic Test: patients with suspected or confirmed gastric cancer who have undergone 18F-FAPI PET/CT and MRI (non-contrast + contrast-enhanced scans) Sponsors: First Affiliated Hospital of Zhejiang University Not yet recruiting

• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

  Conditions: Large-Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Neuroendocrine Carcinoma Interventions: Drug: Benmelstobart+ Anlotinib+ Platinum + Etoposide Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting

• Sarcopenia Predictors in Patients With COPD

  Conditions: COPD (Chronic Obstructive Pulmonary Disease); Sarcopenia; Frailty Sponsors: Hacettepe University; Bursa City Hospital Completed

• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  Conditions: Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma; Recurrent or Refractory; Solid Tumors Interventions: Drug: Autologous B7-H3 CAR T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: National Cancer Institute (NCI) Not yet recruiting

• Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

  Conditions: Vestibular Schwannoma Sponsors: Akouos, Inc.; Eli Lilly and Company Enrolling by invitation

• Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

  Conditions: Breast Cancer Interventions: Behavioral: Remotely Delivered Cognitive Behavioral Stress Management Intervention (R-CBSM); Behavioral: Standard of Care Survivorship Care Planning Sponsors: University of Miami; National Cancer Institute (NCI) Not yet recruiting

• Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors

  Conditions: Breast Cancer Interventions: Behavioral: Breath-Body-Mind (BBM); Behavioral: Survivorship education program (SEP) Sponsors: University of Alabama at Birmingham Not yet recruiting

• Unveiling the Role of Intestinal Parasitic Infections in Childhood Malnutrition in Assiut Governorate.

  Conditions: Malnourished Children Sponsors: Assiut University Not yet recruiting

• Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing

  Conditions: Late-Life Depression Interventions: Dietary Supplement: L-serine supplementation; Other: Placebo Sponsors: IRCCS Centro San Giovanni di Dio Fatebenefratelli Recruiting

• Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

  Conditions: Meningioma; Glioblastoma; Acoustic Neuroma; Brain Cancer; Pituitary Adenoma Interventions: Drug: Panitumumab-IRDye800 Sponsors: Eben Rosenthal Not yet recruiting

• Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

  Conditions: Oligometastatic Prostate Cancer Interventions: Radiation: Metastasis-directed radiotherapy; Drug: Rezvilutamide + ADT; Procedure: Radical prostatectomy Sponsors: Fudan University; Jiangsu Hengrui Pharmaceutical Co., Ltd. Not yet recruiting

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: Biological: ML261 Sponsors: Moonlight Bio, Inc Not yet recruiting

• Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

  Conditions: PONV; Cerebellopontine Angle Tumor; Microvascular Decompression Surgery; Postoperative Analgesia Interventions: Drug: Oliceridine; Drug: Sufentanil Sponsors: Xuanwu Hospital, Beijing Not yet recruiting

• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

  Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV Interventions: Drug: ASTX727 + retifanlimab Sponsors: University of Wisconsin, Madison Not yet recruiting

• TheraSphere Japan Pre-Market Study

  Conditions: Liver Neoplasms Interventions: Device: TheraSphere Y-90 glass microsphere Sponsors: Boston Scientific Corporation Recruiting

• Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  Conditions: Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma; Small Cell Carcinoma Interventions: Drug: Tarlatamab; Drug: Sacituzumab Govitecan Sponsors: National Cancer Institute (NCI) Not yet recruiting

• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  Conditions: Neuroendocrine Tumors Sponsors: Ipsen Recruiting

• Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

  Conditions: Healthy (Controls); Healthy Volunteers; Neuroendocrine (NE) Tumors Interventions: Drug: 68Ga-Dotatate Sponsors: Akiva Mintz Recruiting

• Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  Conditions: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Small Cell Lung Cancer (SCLC); Gastroenteropancreatic NEC (GEP NEC); NEC of the Bladder; Other DLL3 Expressing epNEC Interventions: Drug: [212Pb]Pb-MP0712; Other: [203Pb]Pb-MP0712 Sponsors: Molecular Partners AG; Orano Med LLC Recruiting

• Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

  Conditions: Reproductive Disorder; Neurodegeneration; SARS-CoV 2 Interventions: Drug: Kisspeptin 112-121 Sponsors: Stephanie B. Seminara, MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Recruiting

• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET; Solid Tumor; Somatostatin Receptor Interventions: Drug: RYZ401 Sponsors: RayzeBio, Inc. Recruiting

• Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

  Conditions: Medullary Thyroid Cancer (MTC); Cultural Adaptation Interventions: Other: Interviews Sponsors: M.D. Anderson Cancer Center Recruiting

• Durvalumab as Consolidation for Patients LS-SCLC

  Conditions: Small Cell Lung Cancer Limited Stage Interventions: Drug: Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance Sponsors: Qian Chu Recruiting

• Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

  Conditions: Small Cell Lung Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; Neuroendocrine Prostate Cancer; Gastroenteropancreatic Neuroendocrine Carcinoma Interventions: Drug: 225Ac-ETN029; Drug: 111In-ETN029 Sponsors: Novartis Pharmaceuticals Recruiting

• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) Interventions: Drug: Zanzalintinib; Drug: Everolimus Sponsors: Exelixis Recruiting

• A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

  Conditions: Neuroendocrine Tumor of the Lung; Neuroendocrine Carcinoma of Lung; Neuroendocrine Carcinoma; Neuroendocrine Carcinoma of Prostate Interventions: Diagnostic Test: PET/CT; Biological: 177Lu-DTPA-SC16.56 Sponsors: Memorial Sloan Kettering Cancer Center Not yet recruiting

• Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

  Conditions: Major Depressive Disorder (MDD); Rumination Interventions: Drug: Escitalopram; Drug: Aripiprazole 5mg Sponsors: Central South University; Second Xiangya Hospital of Central South University; National Natural Science Foundation of China Active, not recruiting

• Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

  Conditions: Neuroendocrine Carcinomas (NEC); Neuroendocrine Carcinoma of Pancreas; Neuroendocrine Carcinoma of Prostate Interventions: Drug: Tarlatamab Sponsors: Inkeun Park; Seoul National University Hospital; Severance Hospital; Samsung Medical Center Recruiting

• A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

  Conditions: Tumor Hyperinsulinism (Tumor HI) Interventions: Drug: Ersodetug Sponsors: Rezolute Recruiting

• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

  Conditions: Pancreatic Carcinoma; Pancreatic Neoplasm Interventions: Procedure: Biospecimen Collection; Procedure: Distal Pancreatectomy; Drug: Lanreotide; Other: Questionnaire Administration; Other: Saline Sponsors: SWOG Cancer Research Network; National Cancer Institute (NCI) Recruiting

• Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

  Conditions: DLL3-expressing Tumors; Advanced Tumors Interventions: Drug: Tarlatamab treatment Sponsors: Jonsson Comprehensive Cancer Center; Amgen Recruiting

• Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study

  Conditions: Neuroendocrine (NE) Tumors; Metastasis; Bowel Obstruction Interventions: Other: Histopathological review Sponsors: Insel Gruppe AG, University Hospital Bern Recruiting

• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  Conditions: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Interventions: Radiation: [177Lu]Lu-DOTA-TATE; Drug: Octreotide LAR Sponsors: Novartis Pharmaceuticals Recruiting

• Effects of TAP and QLB-1 Blocks on Opioid Consumption

  Conditions: Postoperative Pain Interventions: Procedure: Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block Sponsors: Başakşehir Çam & Sakura City Hospital Completed

• Agnostic Therapy in Rare Solid Tumors

  Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor Interventions: Drug: Nivolumab Sponsors: Instituto do Cancer do Estado de São Paulo; Financiadora de Estudos e Projetos Recruiting

• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

  Conditions: Solid Tumor Cancer; Medulloblastoma; High Risk Neuroblastoma; High Grade Gliomas; Meningioma; Paraganglioma; Pheochromocytoma; Neuroendocrine Tumours (NET); Adrenal Tumours; DIPG; Glioblastoma; Glioblastoma (GBM); Osteosarcoma Recurrent; Carcinoma Adrenal; Synovial Sarcomas; Esthesioneuroblastoma; Neuroblastoma Recurrent; Solid Tumor Refractory to Conventional Treatment; Medulloblastoma Recurrent; Paraganglioma/ Phaeochromocytoma Interventions: Drug: Olaparib; 177Lu-DOTATATE Sponsors: Fundación de investigación HM Recruiting

• Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

  Conditions: FHA (Functional Hypothalamic Amenorrhea) Interventions: Drug: Romosozumab; Drug: Placebo; Drug: Zoledronic acid Sponsors: Massachusetts General Hospital Recruiting

• Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

  Conditions: Vestibular Schwannoma Interventions: Combination Product: AAVAnc80-antiVEGF via Akouos Delivery Device Sponsors: Akouos, Inc.; Eli Lilly and Company Recruiting

• Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

  Conditions: Extensive Stage Small Cell Lung Cancer Interventions: Drug: Tarlatamab Sponsors: Amgen Active, not recruiting